GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Total Current Liabilities

Rosetta Genomics (Rosetta Genomics) Total Current Liabilities : $2.71 Mil (As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Rosetta Genomics's total current liabilities for the quarter that ended in Jun. 2017 was $2.71


Rosetta Genomics Total Current Liabilities Historical Data

The historical data trend for Rosetta Genomics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Total Current Liabilities Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 1.94 2.21 2.80 3.80

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.45 3.05 3.63 3.80 2.71

Rosetta Genomics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Rosetta Genomics's Total Current Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=3.749+0.055
+Other Current Liabilities+Current Deferred Liabilities
=-4.4408920985006E-16+0
=3.80

Rosetta Genomics's Total Current Liabilities for the quarter that ended in Jun. 2017 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.001+0.055
+Other Current Liabilities+Current Deferred Liabilities
=0.658+0
=2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Rosetta Genomics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458